Original Title: Polymer-Free Biolimus A9-Coated Stents in the Treatment of De Novo Coronary Lesions4- and 12-Month Angiographic Follow-Up and Final 5-Year Clinical Outcomes of the Prospective, Multicenter BioFreedom FIM Clinical Trial CME. Reference: Ricardo A. Costa et al. J Am Coll Cardiol Intv. 2016;9(1):51-64. The purpose of this study was to assess the efficacy and long<a href="https://solaci.org/en/2016/01/26/polymer-free-biolimus-coated-stent-5-year-outcomes/" title="Read more" >...</a>
Original Title: “Long-term outcomes of routine versus provisional T-stenting for de novo coronary bifurcation lesions: five-year results of the Bifurcations Bad Krozingen I study”. Authors: Miroslaw Ferenc, MD; Mohamed Ayoub, MD; Hans-Joachim Büttner, MD; Michael Gick, MD; Thomas Comberg, MD; Jürgen Rothe, MD; Christian M. Valina, MD; Willibald Hochholzer, MD; Franz-Josef Neumann, MD. Division of Cardiology and<a href="https://solaci.org/en/2015/12/28/long-term-outcomes-of-routine-vs-provisional-t-stenting-for-de-novo-coronary-bifurcations-five-year-outcomes-of-the-bbk-i-trial/" title="Read more" >...</a>
Original Title: Benefits and Risks of Extended Dual Antiplatelet Therapy after Everolimus-Eluting Stents. For the Dual Antiplatelet Therapy (DAPT) Study Investigators. Reference: James B. Hermiller et al. JACC: Cardiovascular Interventions 2015, online before print. The DAPT study had shown that continued aspirin plus thienopyridine beyond a year reduces ischemic events. Given the fairly low rate of thrombosis<a href="https://solaci.org/en/2015/12/11/dual-antiplatelet-therapy-after-everolimus-eluting-stenting/" title="Read more" >...</a>
Original Title: Sustained Durability of Treatment Effect Using a Drug-Coated Balloon for Femoropopliteal Lesions. 24-Month Results of IN.PACT SFA. Reference: John R. Laird et al. J Am CollCardiol. 2015 [Epub ahead of print]. The IN.PACT SFA studies and follows up patients treated with IN.PACT Admiral DCB (Medtronic®) for superficial femoral artery (SFA) and popliteal artery disease.<a href="https://solaci.org/en/2015/11/29/sustained-benefit-of-treatment-with-drug-coated-balloon-for-femoropopliteal-lesions-in-pact-sfa-results-at-24-months/" title="Read more" >...</a>
Original Title: Proton Pump Inhibitors, Platelet Reactivity, and Cardiovascular Outcomes After Drug-Eluting Stents in Clopidogrel-Treated Patients. The ADAPT-DES Study. Some proton pump inhibitors interfere with clopidogrel metabolism and could attenuate P2Y12 reception. Prior observational and randomized studies have reported contradicting results on the clinical significance of this drug interaction. The aim of this trial was<a href="https://solaci.org/en/2015/11/23/adapt-des-proton-pump-inhibitors-and-clopidogrel-in-patients-with-des/" title="Read more" >...</a>
Original Title: Everolimus-Eluting Bioresorbable Scaffolds for Coronary Artery Disease. Reference: Stone, M.D. for the ABSORB III Investigators. N Engl J Med 2015;373:1905-1915. The ABSORB III is part of a series of randomized studies that test bioresorbable scaffolds in the clinical practice (ABSORB II, EVERBIO II, ABSORB Japan, and ABSORB IV). 2008 patients were randomized; 60% had<a href="https://solaci.org/en/2015/11/20/absorb-iii-everolimus-eluting-bioresorbable-scaffolds-for-coronary-artery-disease/" title="Read more" >...</a>
Original Title: Individualizing Treatment Duration of Dual Antiplatelet Therapy after Percutaneous Coronary Intervention: An Analysis from the DAPT Study. Presenter: Yeh RW. Optimal dual antiplatelet therapy duration for patients receiving stents has started to become clearer, but a new scoring method (DAPT Score) may help single out patients who could either benefit or suffer from extended<a href="https://solaci.org/en/2015/11/20/dapt-substudy-score-to-personalize-optimal-dual-antiaggregation-therapy-duration/" title="Read more" >...</a>
Original Title: Polymer-free Drug-Coated Coronary Stents in Patients at High Bleeding Risk Reference: Philip Urban et al. N Engl J Med. 2015 Oct 14. [Epub ahead of print]. High bleeding risk patients undergoing PCI usually receive conventional bare metal stents (BMS) to allow the shortest possible DAPT (dual antiplatelet therapy), usually a month long. This<a href="https://solaci.org/en/2015/11/16/polymer-free-drug-coated-stent-in-high-bleeding-risk-patients-with-only-one-month-dapt/" title="Read more" >...</a>
Edición Especial | Congreso SOLACI-SOCIME 2015, in partnership with TCT 1. Reparación endovascular de la patología de aorta torácica a) Tratando anatomías complejas con TEVAR y EVAR b) El valor de la imagen de la tomografía computada de alta resolución en el diagnóstico y detección de complicaciones en pacientes con síndrome aórtico agudo c) La<a href="https://solaci.org/en/2015/11/12/educational-journal-n-103/" title="Read more" >...</a>
Fundamentos: O objetivo desse estudo apresentado na sessão First Report Investigations foi comparar a eficácia anti reestenose da pré-dilatação com scoring balloon versus balão convencional antes do tratamento com balão com cobertura de Paclitaxel em pacientes com reestenose após implante de stent farmacológico. Métodos e resultados: Foi um estudo multicêntrico, prospectivo e randomizado que incluiu pacientes com<a href="https://solaci.org/en/2015/10/13/isar-desire-4-balon-liberador-de-paclitaxel-en-reestenosis-intrastent-de-un-des-2/" title="Read more" >...</a>